CN115047117B - 一种同时测定利奈唑胺中3种遗传毒杂质的检测方法 - Google Patents
一种同时测定利奈唑胺中3种遗传毒杂质的检测方法 Download PDFInfo
- Publication number
- CN115047117B CN115047117B CN202210840152.7A CN202210840152A CN115047117B CN 115047117 B CN115047117 B CN 115047117B CN 202210840152 A CN202210840152 A CN 202210840152A CN 115047117 B CN115047117 B CN 115047117B
- Authority
- CN
- China
- Prior art keywords
- impurity
- mobile phase
- solution
- linezolid
- regulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012535 impurity Substances 0.000 title claims abstract description 134
- 238000001514 detection method Methods 0.000 title claims abstract description 43
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 title claims abstract description 40
- 229960003907 linezolid Drugs 0.000 title claims abstract description 40
- 230000002068 genetic effect Effects 0.000 title claims abstract description 21
- 239000003053 toxin Substances 0.000 title claims abstract description 9
- 231100000765 toxin Toxicity 0.000 title claims abstract description 9
- 239000000243 solution Substances 0.000 claims abstract description 52
- 230000001105 regulatory effect Effects 0.000 claims abstract description 20
- 239000007788 liquid Substances 0.000 claims abstract description 14
- 231100000331 toxic Toxicity 0.000 claims abstract description 12
- 230000002588 toxic effect Effects 0.000 claims abstract description 12
- 238000010828 elution Methods 0.000 claims abstract description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000945 filler Substances 0.000 claims abstract description 6
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000741 silica gel Substances 0.000 claims abstract description 5
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 13
- 238000005303 weighing Methods 0.000 claims description 11
- 238000007865 diluting Methods 0.000 claims description 9
- 239000013558 reference substance Substances 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 6
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 6
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- 239000008055 phosphate buffer solution Substances 0.000 claims description 4
- FQGIBHQUVCGEAC-UHFFFAOYSA-N 3-Fluoro-4-morpholinoaniline Chemical group FC1=CC(N)=CC=C1N1CCOCC1 FQGIBHQUVCGEAC-UHFFFAOYSA-N 0.000 claims description 2
- 230000001276 controlling effect Effects 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 239000012488 sample solution Substances 0.000 claims description 2
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical group C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 238000004458 analytical method Methods 0.000 abstract description 3
- 239000012085 test solution Substances 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 239000012071 phase Substances 0.000 description 31
- 238000012360 testing method Methods 0.000 description 20
- 239000000523 sample Substances 0.000 description 17
- 238000011084 recovery Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007674 genetic toxicity Effects 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- DUILGEYLVHGSEE-ZETCQYMHSA-N 2-[[(2s)-oxiran-2-yl]methyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C[C@H]1CO1 DUILGEYLVHGSEE-ZETCQYMHSA-N 0.000 description 1
- 208000037088 Chromosome Breakage Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000005886 chromosome breakage Effects 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 231100000089 gene mutation induction Toxicity 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 231100000175 potential carcinogenicity Toxicity 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
Description
序号 | 杂质K峰面积 | 杂质M峰面积 | 杂质L峰面积 |
1 | 9078 | 22023 | 35154 |
2 | 9073 | 22089 | 34840 |
3 | 9079 | 22081 | 34723 |
4 | 9056 | 22016 | 34651 |
5 | 9045 | 22028 | 34428 |
6 | 9088 | 21892 | 34302 |
RSD(%) | 0.18 | 0.32 | 0.87 |
相当于供试品浓度(%) | 浓度(μg/ml) | 峰面积 |
0.0033 | 0.065 | 17337 |
0.0025 | 0.049 | 13143 |
0.0016 | 0.033 | 8573 |
0.0008 | 0.016 | 4417 |
0.0003 | 0.007 | 1708 |
0.0002 | 0.003 | 1089 |
相当于供试品浓度(%) | 浓度(μg/ml) | 峰面积 |
0.00330 | 0.066 | 41971 |
0.00248 | 0.050 | 31752 |
0.00165 | 0.033 | 20874 |
0.00083 | 0.017 | 10489 |
0.00033 | 0.007 | 4381 |
0.00005 | 0.0010 | 589 |
相当于供试品检测浓度% | 浓度(μg/ml) | 峰面积 |
0.0030 | 0.061 | 65295 |
0.00228 | 0.046 | 49121 |
0.00152 | 0.030 | 31742 |
0.00076 | 0.015 | 16088 |
0.00030 | 0.006 | 6227 |
0.00003 | 0.0006 | 557 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210840152.7A CN115047117B (zh) | 2022-07-18 | 2022-07-18 | 一种同时测定利奈唑胺中3种遗传毒杂质的检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210840152.7A CN115047117B (zh) | 2022-07-18 | 2022-07-18 | 一种同时测定利奈唑胺中3种遗传毒杂质的检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115047117A CN115047117A (zh) | 2022-09-13 |
CN115047117B true CN115047117B (zh) | 2023-06-16 |
Family
ID=83167189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210840152.7A Active CN115047117B (zh) | 2022-07-18 | 2022-07-18 | 一种同时测定利奈唑胺中3种遗传毒杂质的检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115047117B (zh) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013024398A2 (en) * | 2011-08-12 | 2013-02-21 | Alembic Pharmaceuticals Limited | An improved method for the quantitative determination of linezolid |
CN103145698B (zh) * | 2013-03-01 | 2015-09-09 | 江西同和药业股份有限公司 | 一种利伐沙班中间体的制备方法及利伐沙班的新合成方法 |
RU2015136816A (ru) * | 2013-03-05 | 2017-04-07 | Ф. Хоффманн-Ля Рош Аг | Противовирусные соединения |
CN111983055B (zh) * | 2020-07-28 | 2022-05-31 | 安徽联创生物医药股份有限公司 | 一种用hplc分离测定利伐沙班中间体有关物质的方法 |
CN113588848B (zh) * | 2021-07-21 | 2023-06-06 | 江苏吴中医药集团有限公司 | 利奈唑胺葡萄糖溶液的前处理溶液、前处理方法和检测方法 |
CN114414676B (zh) * | 2021-12-23 | 2023-05-30 | 重庆华邦胜凯制药有限公司 | 一种lc-ms/ms法分离测定利奈唑胺中间体z1中n-亚硝基吗啉的方法 |
-
2022
- 2022-07-18 CN CN202210840152.7A patent/CN115047117B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN115047117A (zh) | 2022-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109580850A (zh) | 一种分离与测定磷酸奥司他韦及其特定杂质的高效液相色谱方法 | |
CN109387587B (zh) | 一种l-2-氨基-5-胍基戊酸对映异构体的检测方法 | |
CN113866337B (zh) | 一种分离与测定磷酸奥司他韦同分异构体的质量分析方法 | |
CN109580825B (zh) | 消旋卡多曲中对甲苯磺酸酯类物质的检测方法 | |
CN115047117B (zh) | 一种同时测定利奈唑胺中3种遗传毒杂质的检测方法 | |
CN110596274B (zh) | 一种头孢曲松钠中2-巯基苯并噻唑的检测方法 | |
CN106198819B (zh) | 顶空气相色谱法测定西格列汀原料药中残留溶剂的方法 | |
CN113820409B (zh) | 一种莫西沙星母核中有关物质的检测方法 | |
CN113049687A (zh) | 一种盐酸氨溴索原料和注射液有关物质的检测方法 | |
CN106546689A (zh) | 一种琥珀酸曲格列汀原料药及其制剂对映异构体的hplc分析方法 | |
CN116242929A (zh) | 同时测定红花药物组合物中9种成分的方法 | |
CN106018617B (zh) | 一种用液相色谱法分离测定盐酸维拉佐酮中2-氯-1-甲基吡啶鎓碘化物含量的方法 | |
CN115372528B (zh) | 一种同时测定呋喃妥因中多种杂质的检测方法 | |
CN111380991B (zh) | 一种检测维生素c药物中降解杂质含量的方法 | |
CN112213418A (zh) | 索非布韦中有关物质的检测方法 | |
CN113960201B (zh) | 一种恩替卡韦中4-二甲氨基吡啶的检测方法 | |
CN113899841B (zh) | 银杏叶提取中间体或其制剂中松脂醇二葡萄糖苷的检测方法 | |
CN117907488A (zh) | 一种舒更葡糖钠基因毒性杂质的分析方法 | |
CN115792047B (zh) | 一种磷酸特地唑胺中间体有关物质的检测方法 | |
CN112034058B (zh) | 一种长春胺中异构体杂质的检测方法 | |
CN115876934A (zh) | 一种达格列净sm-1中基因毒性杂质溴乙烷的检测方法 | |
CN116500160A (zh) | 一种测定头孢他啶中甲酸和/或乙酸含量的方法 | |
CN111257441B (zh) | 一种帕瑞昔布钠合成工艺杂质的检测方法 | |
CN110850012B (zh) | 一种1-(2,3-二氯苯基)哌嗪盐酸盐及其有关物质的检测方法 | |
CN118067860A (zh) | 一种依帕司他片中有关物质的检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240315 Address after: No. 22, Yongwang Road, Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing 102600 Patentee after: Beijing Yunpeng Pengcheng Pharmaceutical Technology Co.,Ltd. Country or region after: China Patentee after: Yunpeng Pharmaceutical Group Co.,Ltd. Address before: No. 22, Aeon Road, Daxing Biomedical Industry Base, Zhongguancun Science and Technology Park, Daxing District, Beijing 102600 Patentee before: Beijing Yunpeng Pengcheng Pharmaceutical Technology Co.,Ltd. Country or region before: China |